HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).

Abstract
Cytokine stimulation induces proliferation and growth of acute myeloid leukemia (AML) blasts and high levels of cytokines have been associated with poor prognosis in AML. The Jak-Stat pathway constitutes a major mediator of cytokine activity. We investigated whether WP-1034, a novel Jak-Stat inhibitor, is active against AML blasts. OCIM2 and fresh AML cells were incubated with 1 to 6 microM WP-1034 to determine its effect on proliferation. WP-1034 effectively inhibited proliferation of OCIM2 cells and fresh AML samples. We then analyzed the expressions of Stat 1, 3, and 5, as well as Phospho-Stat 1, 3, and 5 by Western immunoblotting after incubation of OCIM2 cells without and with 1 to 10 microM WP-1034 for 2 hours, and at 5 microM from 20 minutes up to 4 hours and found that WP-1034 blocked Stat 3 and 5 activation. Analysis of cell cycle status by PI staining and flow cytometry showed that WP-1034 caused cell cycle arrest of OCIM2 cells in sub-Go phase. We then evaluated the induction of apoptosis of OCIM2 cells following incubation with WP-1034 at 3 to 6 microM by annexin V-CY5 assay and analyzed caspase 3 and PARP cleavage using Western immunoblotting. We found that WP-1034 induced apoptosis of OCIM2 cells and that induction of apoptosis involved cleavage of caspase 3 and the DNA repair enzyme poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP). Taken together, our data suggest that WP-1034 is a potent inhibitor of AML cell proliferation by inhibition of Stat 3 and 5 and induction of caspase-dependent apoptosis.
AuthorsStefan Faderl, Alessandra Ferrajoli, David Harris, Quin Van, Waldemar Priebe, Zeev Estrov
JournalAnticancer research (Anticancer Res) 2005 May-Jun Vol. 25 Issue 3B Pg. 1841-50 ISSN: 0250-7005 [Print] Greece
PMID16158916 (Publication Type: Journal Article)
Chemical References
  • Acrylamides
  • Antineoplastic Agents
  • DNA-Binding Proteins
  • Milk Proteins
  • Nitriles
  • Protein Kinase Inhibitors
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • STAT5 Transcription Factor
  • Trans-Activators
  • WP-1034
  • Protein-Tyrosine Kinases
  • JAK1 protein, human
  • Janus Kinase 1
  • CASP3 protein, human
  • Caspase 3
  • Caspases
Topics
  • Acrylamides (pharmacology)
  • Acute Disease
  • Adult
  • Aged
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Caspase 3
  • Caspases (metabolism)
  • Cell Cycle (drug effects)
  • Cell Growth Processes (drug effects)
  • Cell Line, Tumor
  • DNA-Binding Proteins (antagonists & inhibitors)
  • Enzyme Activation (drug effects)
  • Female
  • Humans
  • Janus Kinase 1
  • Leukemia, Erythroblastic, Acute (drug therapy, enzymology, pathology)
  • Leukemia, Myeloid (drug therapy, enzymology, pathology)
  • Male
  • Milk Proteins (antagonists & inhibitors)
  • Nitriles (pharmacology)
  • Protein Kinase Inhibitors (pharmacology)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • STAT3 Transcription Factor
  • STAT5 Transcription Factor
  • Signal Transduction (drug effects)
  • Trans-Activators (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: